1. Introduction {#sec0001}
===============

With the world population aging, the incidence of dementia, especially the most common form, Alzheimer\'s disease (AD), is estimated to increase markedly, which will cause enormous health and economic crises. Unfortunately, there are only symptomatic treatments at present. Much previous research has demonstrated that the pathologic processes of AD precede the first symptoms of cognitive decline ([@bib0030]). Some elderly patients who have cognitively declined, but who do not meet the diagnostic criteria for AD, are often known to have mild cognitive impairment (MCI) ([@bib0001]; [@bib0036]; [@bib0037]), which generally represents a prodromal phase of AD. Over 50 percent of these MCI individuals progress to AD within five years ([@bib0007]). It is now widely believed that the Aβ proteins and the tau proteins can synergistically promote the progression of normal neurons to AD as their accumulation into plaques and tangles ([@bib0002]). Furthermore, MCI can be classified into amnestic (aMCI) and non-amnestic subtypes (naMCI) with different structures ([@bib0005]). Compared to the naMCI subtype, the aMCI subtype has a higher conversion rate to AD ([@bib0008]), whereas the naMCI subtype is prone to progress to other dementia subtypes, such as vascular dementia ([@bib0009]). Currently, it is fully recognized ([@bib0020]) that the continued development of new unrecognized biomarkers that can reliably diagnose MCI patients and predict their conversion to AD ([@bib0006]; [@bib0032]; [@bib0033]; [@bib0034]; [@bib0056]; [@bib0058]) are deeply needed, which makes early intervention possible and may greatly improve the prognosis for AD patients.

Amide proton transfer-weighted (APTw) MRI, a specific type of chemical exchange saturation transfer (CEST) imaging ([@bib0024]; [@bib0025]; [@bib0050]; [@bib0064]), is a promising molecular imaging technique that can noninvasively detect cellular endogenous mobile proteins and peptides ([@bib0061]). Since first reported in 2003 ([@bib0062], [@bib0063]), APT imaging has been researched as an imaging biomarker for several diseases, ranging from brain tumors ([@bib0003]; [@bib0021], [@bib0022]; [@bib0047]) to other non-oncologic neurologic diseases, such as stroke ([@bib0013]; [@bib0018]), Parkinson\'s disease ([@bib0026]), and traumatic brain injury ([@bib0059]). Notably, recent work has shown that the APTw values of the bilateral hippocampus were significantly higher in AD patients than in normal controls ([@bib0049]). However, whether APTw MRI can be an effective diagnostic method for MCI is still unknown. This proof-of-concept study aimed to assess the potential of using the APTw signal as a new imaging biomarker for the differentiation of patients with aMCI and healthy controls, with a comparison with conventional magnetization transfer (MT) imaging that is quantified by the MR ratio (MTR) associated with semi-solid macromolecules in tissue ([@bib0014]).

2. Material and methods {#sec0002}
=======================

2.1. Subjects {#sec0003}
-------------

The local institutional review board approved this study, and all subjects gave written, informed consent. Inclusion criteria for the study were as follows: ≥40 years old; diagnosed as aMCI by an experienced neurodegenerative-disease specialist according to the criteria described by [@bib0036] and [@bib0037] and the National Institute of Aging and Alzheimer\'s Association recommendations ([@bib0001]); no history of head trauma, central nervous system infection, or cerebral structural lesions; or no psychiatric diseases and exposure to psychotropic drugs.

2.2. MRI protocol {#sec0004}
-----------------

MR imaging was performed on a 3 Tesla MRI scanner (Achieva; Philips Medical Systems). For the aMCI patients, scanning was implemented immediately after the diagnoses. A single-slice, multi-offset, combined APTw and conventional MT imaging acquisition protocol ([@bib0026]) was applied to the maximum cross-sectional areas of the hippocampus, the pons, the entorhinal cortex, and the thalamus (four slices). The APTw sequence parameters were as follows: block pulse radiofrequency saturation duration = 800 ms; saturation power = 2 µT; repetition time = 3000 ms; field of view = 230 × 220 mm^2^; matrix = 105 × 100 (reconstructed to be 256 × 256); slice thickness = 6 mm; and turbo spin-echo factor = 54. The 32 offsets were, respectively, 0, ±0.25, ±0.5, ±0.75, ±1, ±1.5, ±2 (2), ±2.5 (2), ±3 (2), ±3.25 (2), ±3.5 (6), ±3.75 (2), ±4 (2), ±4.5, ±5, ±6, and +15.6 ppm (the numbers in brackets indicate the number of acquisitions, which was 1 unless specified). The acquisition time of this combined scan was about 12 min (3 min each slice).

2.3. Data analysis {#sec0005}
------------------

The Interactive Data Language (IDL, version 8; Exelis Visual Information Solutions, Inc.) was applied for image analysis. Briefly, the measured MT spectra were corrected for B~0~ field inhomogeneity effects on a voxel-by-voxel basis, as described previously ([@bib0051]). As usual, the semi-solid MTR images were constructed by 1 - M~sat~(+15.6 ppm)/M~0~ (in which M~sat~ and M~0~ indicate, respectively, the imaging signal intensities with and without selective radiofrequency irradiation). The APTw images were constructed by the MTR asymmetry (MTR~asym~) at the offsets of ± 3.5 ppm, namely, MTR~asym~(3.5 ppm) = M~sat~ (−3.5 ppm)/M~0~ - M~sat~ (+3.5 ppm)/M~0~ ([@bib0062], [@bib0063]).

Based on the structural M~sat~(3.5 ppm) and M~0~ images co-registered with APTw for each subject, 12 regions of interest (ROIs) were manually drawn by two radiologists (Z.Z. and G.W., who have had five and 30 years of experience in neurological imaging, respectively). These 12 ROIs were as follows ([Fig. 1](#fig0001){ref-type="fig"}): the hippocampus, the white matter in the temporal lobe and the gray matter in the temporal lobe (the first slice); the pons, the white matter in the occipital lobe and the gray matter in the occipital lobe (the second slice); the entorhinal cortex, the white matter in the frontal lobe and the gray matter in the frontal lobe (the third slice); and the thalamus, putamen and caudate nucleus (the fourth slice). For each subject, the mean MTR value, mean APTw value, and APTw histogram data of both hemispheres were reported.Fig. 1An example of the 12 regions of interest (ROIs) for quantitative analyses. (**a**) The first slice: hippocampus (red), the white matter in the temporal lobe (green), and the gray matter in the temporal lobe (blue); (**b**) the second slice: pons (red), the white matter in the occipital lobe (green), and the gray matter in the occipital lobe (blue); (**c**) the third slice: the entorhinal cortex (red), the white matter in the frontal lobe (green), and the gray matter in the frontal lobe (blue); and (**d**) the fourth slice: the thalamus (red), the putamen (green), and the caudate nucleus (blue). (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)Fig 1

2.4. Statistical analysis {#sec0006}
-------------------------

All data were analyzed by the statistical software SPSS (version 25.0; IBM Corporation). After a test of normality, the chi-square test and independent samples *t*-test were applied to analyze the statistical differences in the demographic, clinical, and quantitative imaging parameters between aMCI patients and normal controls. The receiver-operator-characteristic (ROC) analysis was used to assess the diagnostic performance of APTw values at each ROI. Furthermore, the correlation analysis was performed for the APTw/MTR signals and age. A *P* \< 0.05 was deemed statistically significant.

3. Results {#sec0007}
==========

3.1. Patient demographics {#sec0008}
-------------------------

From December 2017 to October 2018, 18 aMCI patients who met the inclusion criteria and 18 matched normal controls were enrolled and participated in scanning. The descriptive information for these two groups is provided in [Table 1](#tbl0001){ref-type="table"}. There was no difference in age or sex ratio (*P* \> 0.05).Table 1Population statistics for normal and aMCI groups.Table 1ParameterNormal people (*n* = 18)aMCI Patients (*n* = 18)*P* Value**Group age (y)**56.2 ± 8.9 (40--75)62.1 ± 10.3 (40--80)0.074**Age of men (y)**54.6 ± 8.0 (40--65)60.3 ± 12.2 (40--80)0.266**Age of women (y)**57.9 ± 9.9 (44--75)63.6 ± 8.9 (44--76)0.202**Percentage of women**50560.747**MMSE**28.4 ± 1.1 (27--30)25.3 ± 0.8 (24--26)\<0.0001[^1]

3.2. Comparison of APTw images for normal controls and aMCI patients {#sec0009}
--------------------------------------------------------------------

The two examples of MTR and APTw images for the normal controls and for the aMCI patients are shown in [Fig. 2](#fig0002){ref-type="fig"}. Compared to the normal controls, the APTw images of the aMCI patients demonstrated visible, relatively higher APTw signals in most brain regions, corresponding to right-shifted APTw histograms ([Fig. 3](#fig0003){ref-type="fig"}). There were no clearly visual differences between the MTR images of the normal and aMCI groups.Fig. 2MTR images and APTw images for (**a**) a normal adult (male; 46 y) and (**b**) aMCI patient (female; 61 y).Fig 2Fig. 3The average APTw histograms acquired from 12 regions of interest (ROIs) of normal (blue) and aMCI (red) groups. The histograms of aMCI patients were slightly right-shifted compared to those of normal controls in all ROIs (except for the entorhinal cortex). (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)Fig 3

3.3. Quantitative analyses for APTw and MTR data {#sec0010}
------------------------------------------------

[Fig. 4](#fig0004){ref-type="fig"} summarizes differences between ROI-based mean APTw signal intensity values for the normal controls and aMCI patients, based on the independent samples *t*-test. There were significantly higher APTw values in nine of 12 ROIs in aMCI patients than in normal controls: the hippocampus (*P* = 0.0407), the white matter in the temporal lobe (*P* = 0.0027), the gray matter in the temporal lobe (*P* = 0.0155), the pons (*P* = 0.0279), the white matter in the occipital lobe (*P* = 0.0008), the gray matter in the occipital lobe (*P* = 0.0011), the white matter in the frontal lobe (*P* = 0.0012), the thalamus (*P* = 0.0199), and the putamen (*P* = 0.0062). In three remaining ROIs (the entorhinal cortex, the gray matter in the frontal lobe, and the caudate nucleus), the APTw values in the aMCI group showed a trend toward higher levels, but the increases were not statistically significant, compared to the normal control group (*P* \> 0.05).Fig. 4The independent samples *t*-test for the APTw values. The results are shown from the 12 regions of interest (ROIs) in the normal (blue) and aMCI (red) groups. \**P* \< 0.05. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)Fig 4

Differences between ROI-based mean MTR values for the two groups are indicated in [Fig. 5](#fig0005){ref-type="fig"}. The average MTR values of aMCI patients were slightly larger than those of normal controls in almost all ROIs (except for the gray matter in the temporal lobe). However, these MTR values showed significant differences in only three ROIs: the pons (*P* = 0.0409), the thalamus (*P* = 0.0080), and the caudate nucleus (*P* = 0.0386).Fig. 5The independent samples *t*-test for the MTR values. The results are shown from the 12 regions of interest (ROIs) in the normal (blue) and aMCI (red) groups. \**P* \< 0.05. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)Fig 5

3.4. Accuracy of APTw MRI in diagnosing aMCI {#sec0011}
--------------------------------------------

For nine ROIs showing significantly higher APTw values in aMCI patients than in normal controls, the ROC curve analysis ([Fig. 6](#fig0006){ref-type="fig"}) showed that APTw MRI had great potential as a new imaging biomarker for the diagnosis of aMCI patients. The largest areas under the ROC curves ([Table 2](#tbl0002){ref-type="table"}) were 0.88 in the gray matter in the occipital lobe (with an 88.9% sensitivity and a 72.2% specificity at the cutoff APTw signal intensity of −0.47%), and 0.82 in the gray matter in the temporal lobe (with an 88.9% sensitivity and a 77.8% specificity at the cutoff APTw signal intensity of −0.26%) and the white matter in the occipital lobe (with an 83.3% sensitivity and a 72.2% specificity at the cutoff APTw signal intensity of −0.76%) for the noninvasive molecular diagnosis of aMCI.Fig. 6Receiver-operator-characteristic (ROC) analysis of APTw imaging intensities as an imaging biomarker for the diagnosis of aMCI.Fig 6Table 2Diagnostic performance of APTw signals from nine regions of interest (ROIs) in predicting aMCI.Table 2ROIsAUC (95% CI)Sensitivity (95% CI) (%)Specificity (95% CI) (%)PPV (95% CI) (%)NPV (95% CI) (%)Cutoff Value (%)**Hippocampus**0.70 (0.51--0.83)66.7 (41.0--86.7)77.8 (52.4--93.6)75.0 (54.4--88.3)70.0 (53.7--82.4)0.92**White matter in temporal lobe**0.80 (0.63--0.91)100.0 (81.5--100.0)50.0 (26.0--74.0)66.7 (55.8--76.0)100.0−0.53**Gray matter in temporal lobe**0.82 (0.66--0.93)88.9 (65.3--98.6)77.8 (52.4--93.6)80.0 (62.4--90.6)87.5 (64.9--96.4)−0.26**Pons**0.70 (0.52--0.84)61.1 (35.7--82.7)88.9 (65.3--98.6)84.6 (58.6--95.5)69.6 (55.6--80.7)0.82**White matter in occipital lobe**0.82 (0.65--0.93)83.3 (58.6--96.4)72.2 (46.5--90.3)75.0 (58.1--86.7)81.2 (59.7--92.7)−0.76**Gray matter in occipital lobe**0.88 (0.72--0.96)88.9 (65.3--98.6)72.2 (46.5--90.3)76.2 (59.9--87.3)86.7 (63.0--96.1)−0.47**White matter in frontal lobe**0.78 (0.62--0.90)77.8 (52.4--93.6)77.8 (52.4--93.6)77.8 (58.8--89.6)77.8 (58.8--89.6)−0.63**Thalamus**0.72 (0.54--0.85)77.8 (52.4--93.6)61.1 (35.7--82.7)66.7 (51.6--79.0)73.3 (51.8--87.6)0.75**Putamen**0.73 (0.56--0.86)50.0 (26.0--74.0)88.9 (65.3--98.6)81.8 (53.0--94.7)64.0 (52.1--74.4)0.61[^2]

3.5. Age dependencies of cross-sectional APTw/MTR signals {#sec0012}
---------------------------------------------------------

Additional correlation analyses of the APTw and MTR signals of different ages were performed for the two groups ([Table 3](#tbl0003){ref-type="table"} and Supporting Figs. S1--S4). In the normal control group, the APTw values showed significant positive correlations with age in four of 12 ROIs analyzed: the white matter in the temporal lobe (*r* = 0.5869, *P* = 0.0104), the gray matter in the temporal lobe (*r* = 0.5954, *P* = 0.0091), the white matter in the occipital lobe (*r* = 0.7007, *P* = 0.0012), and the white matter in the frontal lobe (*r* = 0.4731, *P* = 0.0474). In almost all remaining ROIs (except for the caudate nucleus), the APTw values indicated a statistically insignificant, increasing trend with age (*r* \> 0, *P* \> 0.05). Furthermore, the MTR values of seven of 12 ROIs (the hippocampus, the white matter in the temporal lobe, the pons, the white matter in the occipital lobe, the gray matter in the occipital lobe, the thalamus, and the caudate nucleus) showed an increasing trend with age (*r* \> 0, *P* \> 0.05).Table 3Correlation results between the APTw/MTR signals and age from 12 regions of interest (ROIs) of normal and aMCI groups.Table 3Normal controlsPatients with aMCI**APTwMTRAPTwMTR*r**P**r**P**r**P**r**P*Hippocampus**0.39710.10280.12290.6271−0.03360.8948−0.41680.0853**White matter in temporal lobe0.58690.0104**0.31530.20250.26660.2848−0.33910.1687**Gray matter in temporal lobe0.59540.0091**−0.18850.4538−0.07650.7630−0.32930.1821**Pons**0.40170.09840.36640.1348−0.26740.2834−0.15740.5327**White matter in occipital lobe0.70070.0012**0.37970.1202−0.03640.8859−0.13590.5909**Gray matter in occipital lobe**0.35010.15440.29950.2272−0.09080.7201−0.32070.1944**Entorhinal cortex**0.25860.3002−0.21080.40110.27230.2743−0.32210.1924**White matter in frontal lobe0.47310.0474**−0.02830.9114−0.27290.2733−0.14700.5605**Gray matter in frontal lobe**0.16420.5150−0.09850.6975−0.14690.5608−0.21240.3975**Thalamus**0.04250.86710.06530.7969−0.10830.66880.00200.9937**Putamen**0.11870.6391−0.00110.99640.15380.5423−0.23290.3524**Caudate nucleus**−0.13670.58870.07210.77620.05370.83250.10960.6652[^3]

In the aMCI group, the APTw values of eight ROIs (the hippocampus, the gray matter in the temporal lobe, the pons, the white matter in the occipital lobe, the gray matter in the occipital lobe, the white matter in the frontal lobe, the gray matter in the frontal lobe, the thalamus) revealed a trend toward decreasing levels with age (*r* \< 0, *P* \> 0.05). Moreover, the MTR values of almost all ROIs (except for the thalamus and caudate nucleus) displayed a trend toward decreasing levels with age (*r* \< 0, *P* \> 0.05).

4. Discussion {#sec0013}
=============

In this study, we have demonstrated the feasibility and value of using the APTw MRI signal as a new imaging biomarker for the diagnosis of aMCI that represents a prodromal phase of AD. It was found that the mean APTw values were significantly higher in 9/12 ROIs in the aMCI patients than those in the normal controls ([Fig. 4](#fig0004){ref-type="fig"}). On the contrary, the MTR values revealed significant differences in only 3/12 ROIs between the normal and aMCI groups ([Fig. 5](#fig0005){ref-type="fig"}). Interestingly, the age dependency analyses showed that these cross-sectional APTw/MTR signals were seemingly age dependent in both groups ([Table 3](#tbl0003){ref-type="table"}). Conventional MT imaging quantified by MTR is designed to detect semi-solid macromolecules that exist in the solid environment of cells, for instance, proteins in the cell membrane and the nucleus ([@bib0014]), while APT imaging is sensitive to mobile proteins in tissues ([@bib0061]). These mobile proteins have a specific amide proton resonance frequency at 3.5 ppm downfield from water, which can be detected by APTw MRI. Theoretically, the larger the concentration of amide protons, the higher the APTw value would be.

A hallmark of neurodegenerative proteinopathies is the accumulation of misfolded proteins in the brain ([@bib0044]; [@bib0052]). According to the amyloid hypothesis, which is currently the predominant theory for the cause of AD ([@bib0012]; [@bib0041]), abnormal accumulation of amyloid beta (Aβ) protein in the brain is the main effect of AD pathogenesis, and tau protein tangle deposition and neurodegeneration are regarded as downstream influences of an imbalance between production and clearance of Aβ protein ([@bib0011]). In addition, the amyloid deposition begins in the basal frontal and temporal lobes while the neurofibrillary tangle deposition starts in the medial temporal lobe, and gradually both of the abnormal proteins spread throughout the entire cerebral cortex ([@bib0038]). Therefore, the ability to image underlying Aβ protein plaques and tau protein neurofibrillary tangles *in vivo* represents a major area of progress for AD research ([@bib0038]). Currently, PET has been able to accurately target Aβ protein ([@bib0040]; [@bib0055]) and tau protein ([@bib0042]; [@bib0043]) in the brain using relevant tracers. The accumulation, aggregation, and eventual insolubility of various proteins, including amyloid beta and tau protein, might provide an observable MT imaging effect ([@bib0035]; [@bib0039]). This molecular mechanism may also account for the APTw results reported in this study; thus, APTw imaging can be a potential means by which to noninvasively visualize the abnormal proteins of aMCI patients *in vivo*.

Further, the APTw values showed significant differences between the two groups in more ROIs than the MTR values. The APTw values in nine ROIs were significantly higher in the aMCI group than in the normal control group, suggesting that the abnormal proteins had accumulated in the corresponding nine areas of aMCI patients. The entorhinal cortex, the earliest area invaded by tau proteins ([@bib0038]), and the most heavily damaged cortex in Alzheimer\'s disease ([@bib0048]), should have had the higher APTw value in the aMCI group. However, the APTw value of the entorhinal cortex did not show significant differences between the two groups. The reason may be attributable to the following: the abnormal protein deposition gradually causes damage and the death of entorhinal cortex neurons ([@bib0002]). At a certain stage, the neuronal death may cause the mobile protein loss, as observed in the substantia nigra in Parkinson\'s disease ([@bib0026]). The exact mechanism needs to be explored in the future.

In the normal control group, both the APTw and MTR values showed weak positive correlations or trends toward increasing levels with age in most brain regions (11 of 12 ROIs for APTw, and 7 of 12 ROIs for MTR) ([Table 3](#tbl0003){ref-type="table"}). It is known that there is no significant neuronal loss during aging in normal brains ([@bib0028]), and cerebral volume loss with advancing age is attributed to changes in neuronal size and dendritic arborization ([@bib0046]). Thus, the concentration of mobile proteins and semi-solid macromolecules in cerebral tissue may become relatively higher with increasing age, which may explain the positive correlations in the normal control group. On the contrary, in the aMCI group, both the APTw and MTR values showed a trend toward decreasing levels with age for most brain regions (8/12 ROIs for APTw, and 10/12 ROIs for MTR) ([Table 3](#tbl0003){ref-type="table"}). The loss of neurons in aMCI is induced by Aβ and tau protein deposition ([@bib0002]). Therefore, we inferred that more neurons in the cerebrum of aMCI patients are lost with advancing age, which may represent a greater possibility of conversion to AD. From the above analysis, we deduced that the higher, decreasing APTw and MTR values in aMCI patients and the lower, increasing APTw and MTR values in normal controls would converge at a certain point with aging. After the convergence point, the APTw and MTR values in aMCI patients may be equal to or even lower than those in normal controls, consistent with a previous report for relatively older subjects ([@bib0029]).

There were some limitations to this study. (i) The number of participants was relatively small in this study. We are planning to perform a further longitudinal study with a larger number of participants. A regression-based analysis approach adjusted for age, mini-mental state examination (MMSE), educational attainment, and any other potential influential factors will be performed in the future. (ii) We acquired four cerebral slices using a single-slice protocol. Thus, the MRI signals in other regions of brain could not be explored in the study. In the future, we plan to increase the coverage of APTw MRI by applying a three-dimensional APT imaging acquisition protocol that has been reported in the literature ([@bib0065]), with which the APTw MRI of the whole brain can be obtained. Further, because of the limited slice, ROI placement was manually performed, which was difficult for cortical grey matters. The three-dimensional APT imaging acquisition protocol in combination with the automatic segmentation may increase the ROI accuracy in the future. (iii) We hypothesize that the abnormal accumulation and aggregation of various proteins, including amyloid beta and tau protein, provided the observed APT imaging effect. It was reported that soluble amyloid beta and tau protein in the AD brain had levels of a few to tens of µM ([@bib0010]; [@bib0031]). In this regard, it should be kept in mind that the observed APTw MRI signal is associated with a large group of cellular proteins, each contributing multiple amide groups, as shown in a previous proteomics study ([@bib0054]). (iv) The APTw signal quantified from MTR~asym~(3.5 ppm), as used in this study, was contaminated with the upfield nuclear Overhauser enhancement signal from mobile and semi-solid protons ([@bib0023]; [@bib0027]), and several possible other effects ([@bib0061]). An alternative APTw imaging analysis or acquisition approach ([@bib0015], [@bib0019]; [@bib0053]; [@bib0057]; [@bib0060]; [@bib0067]) may be used to quantify a pure APT effect in the future studies. A higher MTR ([Fig. 5](#fig0005){ref-type="fig"}) or a lower T~1~ ([@bib0045]) may potentially decrease the corresponding APTw signal. Notably, it has been shown recently that the mixing APTw image contrast is dominated by the APT effect ([@bib0015], [@bib0019]) and the possible influence of water T~1~ on APTw imaging was actually small for the pulse sequence parameters used here ([@bib0017]; [@bib0068]). Crucially, the use of MR fingerprinting may achieve absolute APT parameter quantification for exchange rates and concentrations ([@bib0004]; [@bib0016]; [@bib0066]). It is expected that more pure and quantitative APT MRI approaches have significance for improving the detection accuracy, but this still will have to be validated.

5. Conclusion {#sec0014}
=============

This exploratory study represents the first analysis of the ability to use APTw MRI to detect patients with aMCI. The significant APTw signal differences in the multiple ROIs between aMCI patients and normal controls demonstrated the feasibility of APTw MRI to be used for the noninvasive molecular diagnosis of aMCI, which could make possible early intervention for aMCI, and even AD. Thus, our early results highlight the future potential of the APTw signal as an imaging biomarker for aMCI patients.
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[^1]: Data are means ± standard deviations, with ranges in parentheses; aMCI, amnestic mild cognitive impairment; MMSE, mini-mental state examination.

[^2]: APTw, amide proton transfer-weighted; aMCI, amnestic mild cognitive; AUC, area under the ROC (receiver operator characteristic) curve; CI, confidence interval; PPV, positive predictive value; NPV, negative predictive value.

[^3]: APTw, amide proton transfer-weighted; MTR, magnetization transfer ratio; aMCI, amnestic mild cognitive impairment. Bold values mean *P*  \< 0.05.
